"Novo Nordisk is the world leader in diabetes, and this initiative is of strategic importance both to them and to us," said Professor Anders Hamsten, vice-chancellor at Karolinska Institutet. "The agreement creates a unique opportunity for recruiting young diabetes researchers to Karolinska Institutet."
In a comment to the collaboration agreement, Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk, said: "Together, we will train scientists in exploring basic diabetes research and translating this into new potential treatments for patients. Building upon the unique academic and clinical tradition at Karolinska Institutet and our company's excellence in research and development, the collaboration holds great potential to stimulate innovation and ultimately to improve the lives of the patients."
Novo Nordisk has research and development facilities in Denmark, US, China and India. More than 6,000 employees are involved in research and development activities, many of them working in partnerships with external biotech and academic researchers.
"This agreement is yet another example of Karolinska Institutet's ambition to strengthen collaboration with the business community, in this case Novo Nordisk, one of the leading pharmaceutical companies in the Nordic region," said Professor Hans-Gustaf Ljunggren, dean of research at Karolinska Institutet.
A joint steering committee with members from both Karolinska Institutet and Novo Nordisk will oversee the programme and will be responsible for recruiting researchers.The first four fellows in the programme are expected to start in the autumn of 2015.
Karolinska Institutet is one of the world's leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for over 40% of the medical academic research conducted in Sweden and offers the country's broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 41,500 employees in 75 countries, and markets its products in more than 180 countries.